Meeting report: The international conference on tumor progression and therapeutic resistance

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4475-4484

  El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 7 HYDROXYSTAUROSPORINE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATN 161; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INSULIN RECEPTOR SUBSTRATE 2; IRINOTECAN; LEG 3; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; ON 012380; ON 01910; OXALIPLATIN; PACLITAXEL; PD 0332991; PERIFOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PRODRUG; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; RAF PROTEIN; SELENIUM; SELENOMETHIONINE; SORAFENIB; SULINDAC SULFONE; THAPSIGARGIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VINCRISTINE; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CARDIOTOXICITY; CELL DEATH; CLINICAL TRIAL; COLON ADENOMA; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; HEART DISEASE; HUMAN; INTERNATIONAL COOPERATION; LABORATORY TEST; LEARNING; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNITED STATES;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES;

EID: 19644362501     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0620     Document Type: Conference Paper

References (47)

1. Hutchinson LM, Chang EL, Becker CM, et al. Use of thymosin β15 as a urinary biomarker in human prostate cancer. Prostate. In press 2005.
2. Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 2004;3:729-35.
3. Hu MC-T, Lee D-F, Xia W, et al. IkB kinase promotes tumourigenesis through inhibition of Forkhead transcription factor FOXO3a. Cell 2004;117;225-37.
4. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004;6:459-69.
5. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature Cell Biol 2004;6:931-40.
6. Wang H, Fu W, Im JH, et al. Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004;164:935-41.
7. Im JH, Fu W, Wang H, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004;64:8613-9.
8. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
9. Kerbel RS, Kamen BA. The anti-anglogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
10. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
11. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004;24:985-96.
12. Kuo M-L, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004;18:1862-74.
13. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
14. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytlc leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.
15. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
16. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and Initiates genetic instability. Cancer Cell 2005;7:193-204.
17. Schimmer AD, Welsh K, Plnilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35.
18. Wang Z, Cuddy M, Samuel T, et al. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004;279:48168-76.
19. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. In press 2005.
20. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272-82.
21. Goulet AC, Chigbrow M, Frisk P, Nelson MA. Selenomethionine induces sustained ERK phosphorylation lead to cell cycle arrest in human colon cancer cells. Carcinogenesis 2005;26:109-17.
22. Baker GL, Landis MW, Hinds PW. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 2005;4:330-8.
23. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60.
24. Clapper ML, Coudry J, Chang WC. β-Cateninmediated signaling: a molecular target for early chemopreventive Intervention. Mutat Res 2004;555:97-105.
25. Hensley HH, Chang WC, Clapper ML. Detection and volume determination of colonic tumors in Min mice by magnetic resonance micro-Imaging. Magn Reson Med 2004;52:524-9.
26. Johnson S, Grosshans H, Shingar J, et al. RAS is regulated by the let-7 mlcroRNA family. Cell 2005;120:635-47.
27. Tian X Aruva MR, Qin W, et al. External imaging of CCND1 cancer gene activity In experimental human breast cancer xenografts with Tc- 99 m-peptide-PNA-peptide chimeras. J Nuclear Med 2004;45:2070-82.
28. Tian X, Aruva MR, Qin W, et al. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [99mTc]peptide-peptide nucleic acid-peptide chimera. Bioconjugate Chemistry 2005;16:70-9.
29. Wu HI, Brown JA, Dorie MJ, Lazzeroni L, Brown JM. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C, Cancer Res 2004;64:3940-8.
30. Meng G, Zhao Y, Nag A, et al. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem 2004;279:54230-40,
31. Huyen Y, Zgheib O, Ditullio RA Jr, et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004;432:406-11.
32. Komarova EA, Kondratov RV, Wang K, et al. Dual effect of p53 on radiation sensitivity in vivo; p53 promotes hematopoietic injury, but protects from gastro-Intestinal syndrome in mice. Oncogene 2004;23: 3265-71.
33. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell 2004;6:117-27.
34. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005;102:1992-7.
35. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-61.
36. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62.
37. Sebolt-Leopold JS, Herrera R, Targeting the mitogenactivated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
38. Dai Y, Rahmanl M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol Interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -Independent mechanisms. Blood 2004;104:509-18.
39. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance Is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227-39.
40. Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the nuclear factor-κB pathway to induction of apoptosis in human leukemia cells by histone deacetylase Inhibitors and flavopiridol. Mol Pharmacol 2004;66:956-63.
41. Seenisamy J, Rezler EM, Powell TJ, et al. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc 2004;126:8702-9.
42. Gerner EW, Meyskens FL Jr, Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
43. Blgio IJ, Bown SG. Spectroscopic sensing of cancer and cancer chemotherapy: current status of translational research. Cancer Biol Ther 2004;3:259-67.
44. Cao Y, Wagers A, Beilhack A, et al. Shifting foci of hematopoeisis during reconstitution from single stem cells. Proc Natl Acad Sci U S A 2004;101:221-6.
45. Wang, TD, Mandella MJ, Contag CH, Kino GS. Dual axes confocal fluorescence microscope for in vivo molecular and cellular imaging. J Biomed Optics 2004;9:735-42.
46. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64:6666-72.
47. Fei P, Wang W, Kim SH, et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004;6:597-609.